Hypothesis for the development of immune-related adverse events in immune checkpoint inhibitors therapy

Standard

Hypothesis for the development of immune-related adverse events in immune checkpoint inhibitors therapy. / Orlova, Rashida ; Zhukova, Natalia ; Malkova, Anna ; Shoenfeld, Yehuda.

In: Cancer Treatment and Research Communications, Vol. 31, 100529, 01.01.2022.

Research output: Contribution to journal › Article › peer-review

BibTeX

@article{761dfb9bf1224de389a936de85c59370,

title = "Hypothesis for the development of immune-related adverse events in immune checkpoint inhibitors therapy",

abstract = "There are no explanations for the diversity in the development of certain immune-related adverse events (irAEs) with immune checkpoint inhibitors (ICI). The goal of this study is to search for possible predisposing factors that contribute to the development of certain autoimmune complications during anti-CTLA4 and anti-PD1/PD-L1 therapy. According to the keywords “checkpoint inhibitors, anti-CTLA4, anti-PD1/PD-L1, immune adverse events, paraneoplastic syndrome” the review and original articles published in the international databases to 2021were selected and studied. According to the analysis of the published papers, we consider that a key role in the difference in the types of irAEs lies in the specificity of the drug. The high prevalence of skin and gastrointestinal autoimmune complications can be explained by the presence of gut dysbacteriosis in patients before treatment and developed during the treatment. For the development of specific types of irAEs, a complex of predisposing factors is required, such as HLA-genotype, paraneoplastic syndromes, and the expression of PD-L1 in the thyroid gland in the case of anti-PD1 therapy.",

keywords = "Cancer autoimmunity, Gut dysbacteriosis, ICIs - immune checkpoint inhibitors, irAEs - immune-related adverse events, Paraneoplastic syndrome, Predisposing factors",

author = "Rashida Orlova and Natalia Zhukova and Anna Malkova and Yehuda Shoenfeld",

year = "2022",

month = jan,

day = "1",

doi = "10.1016/j.ctarc.2022.100529",

language = "English",

volume = "31",

journal = "Cancer Treatment and Research Communications",

issn = "2213-0896",

publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Hypothesis for the development of immune-related adverse events in immune checkpoint inhibitors therapy

AU - Orlova, Rashida

AU - Zhukova, Natalia

AU - Malkova, Anna

AU - Shoenfeld, Yehuda

PY - 2022/1/1

Y1 - 2022/1/1

N2 - There are no explanations for the diversity in the development of certain immune-related adverse events (irAEs) with immune checkpoint inhibitors (ICI). The goal of this study is to search for possible predisposing factors that contribute to the development of certain autoimmune complications during anti-CTLA4 and anti-PD1/PD-L1 therapy. According to the keywords “checkpoint inhibitors, anti-CTLA4, anti-PD1/PD-L1, immune adverse events, paraneoplastic syndrome” the review and original articles published in the international databases to 2021were selected and studied. According to the analysis of the published papers, we consider that a key role in the difference in the types of irAEs lies in the specificity of the drug. The high prevalence of skin and gastrointestinal autoimmune complications can be explained by the presence of gut dysbacteriosis in patients before treatment and developed during the treatment. For the development of specific types of irAEs, a complex of predisposing factors is required, such as HLA-genotype, paraneoplastic syndromes, and the expression of PD-L1 in the thyroid gland in the case of anti-PD1 therapy.

AB - There are no explanations for the diversity in the development of certain immune-related adverse events (irAEs) with immune checkpoint inhibitors (ICI). The goal of this study is to search for possible predisposing factors that contribute to the development of certain autoimmune complications during anti-CTLA4 and anti-PD1/PD-L1 therapy. According to the keywords “checkpoint inhibitors, anti-CTLA4, anti-PD1/PD-L1, immune adverse events, paraneoplastic syndrome” the review and original articles published in the international databases to 2021were selected and studied. According to the analysis of the published papers, we consider that a key role in the difference in the types of irAEs lies in the specificity of the drug. The high prevalence of skin and gastrointestinal autoimmune complications can be explained by the presence of gut dysbacteriosis in patients before treatment and developed during the treatment. For the development of specific types of irAEs, a complex of predisposing factors is required, such as HLA-genotype, paraneoplastic syndromes, and the expression of PD-L1 in the thyroid gland in the case of anti-PD1 therapy.

KW - Cancer autoimmunity

KW - Gut dysbacteriosis

KW - ICIs - immune checkpoint inhibitors

KW - irAEs - immune-related adverse events

KW - Paraneoplastic syndrome

KW - Predisposing factors

UR - http://www.scopus.com/inward/record.url?scp=85123948169&partnerID=8YFLogxK

U2 - 10.1016/j.ctarc.2022.100529

DO - 10.1016/j.ctarc.2022.100529

M3 - Article

C2 - 35131574

AN - SCOPUS:85123948169

VL - 31

JO - Cancer Treatment and Research Communications

JF - Cancer Treatment and Research Communications

SN - 2213-0896

M1 - 100529

ER -

ID: 116164373